Krystal Biotech, Inc.
KRYS NASDAQHealthcare ★★★★★Latest Earnings
Date
Aug 3, 2026
ET
EPS Est.
1.70
EPS Actual
1.79
Revenue Est.
$120.9M
Revenue Actual
$119.2M
Next Earnings Report
Date
Nov 2, 2026 · Mon
Time
Pre-market
Fiscal Period
FY2026 Q3
EPS Est.
1.91
Revenue Est.
$129.6M
Company Overview
Krystal Biotech, Inc. (ticker KRYS) is listed on NASDAQ with a market cap of about $10.22B. Its next earnings report (FY2026 Q3) is expected on Nov 2, 2026 (ET), Pre-market, with consensus EPS of 1.91. In the last 15 reported quarters, EPS beat consensus estimates 11 times.
Actual EPS TrendRecently15Term · Feb 27, 2023 → Aug 3, 2026
Feb 27, 2023Range: -1.76 ~ 2.66Aug 3, 2026
Earnings History
| Date | Fiscal Period | EPS Est. | EPS Actual | Revenue Est. | Revenue Actual |
|---|---|---|---|---|---|
| Aug 3, 2026 | -- | 1.70 | 1.79 | $120.9M | $119.2M |
| May 4, 2026 | -- | 1.45 | Above forecast↑1.83 | $112.1M | $116.4M |
| Feb 17, 2026 | -- | 1.62 | 1.70 | $105.3M | $107.1M |
| Nov 3, 2025 | -- | 1.12 | Above forecast↑2.66 | $105.3M | $97.8M |
| Aug 4, 2025 | -- | 1.08 | Above forecast↑1.29 | $95.4M | $96M |
| May 6, 2025 | -- | 1.38 | 1.20 | $106M | $88.2M |
| Feb 19, 2025 | -- | 1.29 | Above forecast↑1.52 | $91.4M | $91.1M |
| Nov 4, 2024 | -- | 0.90 | 0.91 | $91.3M | $83.8M |
| Aug 5, 2024 | -- | 0.50 | 0.53 | $65.3M | $70.3M |
| May 6, 2024 | -- | 0.15 | Below forecast↓0.03 | $47.4M | $45.3M |
| Feb 26, 2024 | -- | -0.38 | Above forecast↑0.30 | $29.2M | $42.1M |
| Nov 6, 2023 | -- | -1.10 | Above forecast↑-0.67 | $28.6M | $8.6M |
| Aug 7, 2023 | -- | -0.42 | Below forecast↓-1.25 | -- | -- |
| May 8, 2023 | -- | -1.41 | Below forecast↓-1.76 | $200000 | -- |
| Feb 27, 2023 | -- | -1.39 | -1.25 | $200000 | -- |
Original Filings (SEC)
8-K2026-08-03 ↗
10-Q2026-08-03 ↗
8-K2026-07-21 ↗
8-K2026-05-20 ↗
8-K2026-05-04 ↗
10-Q2026-05-04 ↗
8-K2026-02-17 ↗
10-K2026-02-17 ↗
Links point to the company's original filings on the U.S. Securities and Exchange Commission (SEC) website.
Report dates are US trading days (Eastern Time); EPS and revenue estimates are market consensus, in USD. This page is for reference only and does not constitute investment advice.
